A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent ...
A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side ...
Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...
Read more on antibody drug conjugates in urothelial carcinoma where enfortumab vedotin and disitamab vedotin show high ...
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...
Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates based on Parabilis’s Helicon™ ...
CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be ...
Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers ADCs have become mainstream therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results